Clincosm LogoSign in Get a demo

Comparison of Vitreous Levels of Acular LS 0.04%, Xibrom 0.09%, and Nevanac 0.1%

Sponsor
Innovative Medical (Industry)
Overall Status
Completed
CT.gov ID
NCT00377546
Collaborator
(none)
1
Location

Study Details

Study Description

Brief Summary

To compare the penetration of three different NSAIDs.

Condition or Disease Intervention/Treatment Phase
Phase 4

Study Design

Study Type:
Interventional
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double

Outcome Measures

Primary Outcome Measures

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    N/A and Older
    Sexes Eligible for Study:
    All
    Inclusion Criteria:

    • Males or females scheduled to undergo Vitrectomy surgery

    • Likely to complete all study visits and able to provide informed consent

    • Visual potential of 20/25 or better

    Exclusion Criteria:

    • Known contraindications to any study medication or ingredients

    • Active ocular diseases or uncontrolled systemic disease

    • Active ocular allergies

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Ophthalmic Consultants of Boston Boston Massachusetts United States 02114

    Sponsors and Collaborators

    • Innovative Medical

    Investigators

    • Principal Investigator: Jeffrey Heier, MD, Ophthalmic Consultants of Boston

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    , ,
    ClinicalTrials.gov Identifier:
    NCT00377546
    Other Study ID Numbers:
    • 5264
    First Posted:
    Sep 18, 2006
    Last Update Posted:
    Sep 25, 2008
    Last Verified:
    Sep 1, 2008
    Keywords provided by , ,
    Retinal Surgery
    Additional relevant MeSH terms:
    Ketorolac
    Nepafenac
    Bromfenac

    Study Results

    No Results Posted as of Sep 25, 2008